Scholarlink

Background <p>Diabetic wounds are a debilitating complication of diabetes mellitus with a high rate of amputation and mortality. 6-Hydroxyhyoscyamine hydrobromide (6-HH) is a belladonna alkaloid with smooth-muscle-relaxing and microcirculation-enhancing properties, yet its role in diabetic wounds remains unknown.</p> Methods <p>In vivo, diabetic wounds were established in streptozotocin (STZ)-induced type 1 diabetic mice, high fat diet (HFD)/STZ-induced type 2 diabetic mice, and <i>db</i>/<i>db</i> diabetic mice to investigate the therapeutic effects of 6-HH, and skin samples were collected for hematoxylin and eosin (H&amp;E) and Masson’s trichrome staining, immunofluorescence, RNA-seq analysis, and western blotting. In vitro, the mechanism of action of 6-HH on cytokines, nuclear factor kappa B (NF-κB) signals, and the interaction between sirtuin 6 (SIRT6) and p65 in lipopolysaccharide (LPS)-induced macrophages were detected by using enzyme-linked immunosorbent assay (ELISA), western blotting, reverse-transcription quantitative polymerase chain reaction (RT-qPCR), immunofluorescence, and immunoprecipitation, while molecular docking was used to evaluate the binding energy between 6-HH and SIRT6 protein. Coculture systems of THP-1 cells–human umbilical vein endothelial cells (HUVECs)/immortalized human keratinocytes (HaCaTs) were established to investigate the effects of 6-HH on cross-talk between macrophages and endothelial cells/keratinocytes. SIRT6-specific inhibitor Oss_128167 was applied in vitro and in vivo to verify the mechanism of 6-HH in diabetic wound healing.</p> Results <p>6-HH exhibited excellent pro-healing effect in the three types of diabetic mouse model. RNA-seq analysis found that 6-HH recovered diabetic-induced aberrant expression changes of genes in the local wounds, especially those related to M1 macrophage polarization with downregulation of Toll-like receptor (TLR) signals and nicotinamide adenine dinucleotide phosphate (NADP<sup>+</sup>) nucleosidase activity. Molecular docking analysis found that 6-HH could effectively bind to the active site of the SIRT6 protein. Remarkably, decline of SIRT6 in M1 macrophages resulted in lysine hyperacetylation, while activation and stabilization of SIRT6 by 6-HH suppressed M1 macrophage polarization and hyperacetylation through inhibiting p65 transcription with deacetylation of p65<sup>Lys310</sup> and H3K9, contributing to improve angiogenesis and re-epithelization through interaction between macrophages and endothelial cells/keratinocytes. However, pharmacological inhibition of SIRT6 reversed the action of 6-HH in macrophages and diabetic wounds.</p> Conclusions <p>Collectively, deacetylase SIRT6 might be a direct pharmacological target of 6-HH that downregulates the hyperacetylated state of macrophages, thus contributing to diabetic wound healing.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting the sirtuin 6–NF-κB p65 axis by 6-hydroxyhyoscyamine hydrobromide: a deacetylation-driven new therapy for diabetic wounds

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月22日

查看全文
  • Junren Chen,
  • Siqi Qin,
  • Ziwei Xing,
  • Feng Wan,
  • Jie Yin,
  • Cheng Peng,
  • Dan Li

摘要

Background

Diabetic wounds are a debilitating complication of diabetes mellitus with a high rate of amputation and mortality. 6-Hydroxyhyoscyamine hydrobromide (6-HH) is a belladonna alkaloid with smooth-muscle-relaxing and microcirculation-enhancing properties, yet its role in diabetic wounds remains unknown.

Methods

In vivo, diabetic wounds were established in streptozotocin (STZ)-induced type 1 diabetic mice, high fat diet (HFD)/STZ-induced type 2 diabetic mice, and db/db diabetic mice to investigate the therapeutic effects of 6-HH, and skin samples were collected for hematoxylin and eosin (H&E) and Masson’s trichrome staining, immunofluorescence, RNA-seq analysis, and western blotting. In vitro, the mechanism of action of 6-HH on cytokines, nuclear factor kappa B (NF-κB) signals, and the interaction between sirtuin 6 (SIRT6) and p65 in lipopolysaccharide (LPS)-induced macrophages were detected by using enzyme-linked immunosorbent assay (ELISA), western blotting, reverse-transcription quantitative polymerase chain reaction (RT-qPCR), immunofluorescence, and immunoprecipitation, while molecular docking was used to evaluate the binding energy between 6-HH and SIRT6 protein. Coculture systems of THP-1 cells–human umbilical vein endothelial cells (HUVECs)/immortalized human keratinocytes (HaCaTs) were established to investigate the effects of 6-HH on cross-talk between macrophages and endothelial cells/keratinocytes. SIRT6-specific inhibitor Oss_128167 was applied in vitro and in vivo to verify the mechanism of 6-HH in diabetic wound healing.

Results

6-HH exhibited excellent pro-healing effect in the three types of diabetic mouse model. RNA-seq analysis found that 6-HH recovered diabetic-induced aberrant expression changes of genes in the local wounds, especially those related to M1 macrophage polarization with downregulation of Toll-like receptor (TLR) signals and nicotinamide adenine dinucleotide phosphate (NADP+) nucleosidase activity. Molecular docking analysis found that 6-HH could effectively bind to the active site of the SIRT6 protein. Remarkably, decline of SIRT6 in M1 macrophages resulted in lysine hyperacetylation, while activation and stabilization of SIRT6 by 6-HH suppressed M1 macrophage polarization and hyperacetylation through inhibiting p65 transcription with deacetylation of p65Lys310 and H3K9, contributing to improve angiogenesis and re-epithelization through interaction between macrophages and endothelial cells/keratinocytes. However, pharmacological inhibition of SIRT6 reversed the action of 6-HH in macrophages and diabetic wounds.

Conclusions

Collectively, deacetylase SIRT6 might be a direct pharmacological target of 6-HH that downregulates the hyperacetylated state of macrophages, thus contributing to diabetic wound healing.

Graphical Abstract